Literature DB >> 363105

The mechanism of timolol in lowering intraocular pressure. In the normal eye.

R L Coakes, R F Brubaker.   

Abstract

A single-drop, double-masked, randomized, placebo-controlled study of the mechanism of the ocular-pressure lowering property of timolol maleate, a beta-adrenergic blocker, was carried out in 23 normal subjects, using fluorophotometry. Timolol suppressed aqueous formation in all subjects. The range of suppression was 13% to 48%, with a mean +/- SD of 34% +/- 9%. The drug had no effect on anterior chamber volume or endothelial permeability to fluorescein and, apparently, had no effect on outflow resistance. No differences were observed between its effect on men and women or between eyes with light and dark irides.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 363105     DOI: 10.1001/archopht.1978.03910060433007

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  47 in total

1.  A comparison of the fixed combination of latanoprost and timolol with the unfixed combination of brimonidine and timolol in patients with elevated intraocular pressure. A six month, evaluator masked, multicentre study in Europe.

Authors:  J García-Sánchez; J-F Rouland; D Spiegel; B Pajic; I Cunliffe; C Traverso; J Landry
Journal:  Br J Ophthalmol       Date:  2004-07       Impact factor: 4.638

Review 2.  Discovery of Molecular Therapeutics for Glaucoma: Challenges, Successes, and Promising Directions.

Authors:  Rebecca K Donegan; Raquel L Lieberman
Journal:  J Med Chem       Date:  2015-09-25       Impact factor: 7.446

3.  Effect of glaucoma medications on 24-hour intraocular pressure-related patterns using a contact lens sensor.

Authors:  Kaweh Mansouri; Felipe A Medeiros; Robert N Weinreb
Journal:  Clin Exp Ophthalmol       Date:  2015-08-16       Impact factor: 4.207

4.  A complex interaction between topical verapamil and timolol on intraocular pressure in conscious rabbits.

Authors:  J Santafé; M J Martínez de Ibarreta; J Segarra; J Melena; M Garrido
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996-07       Impact factor: 3.000

Review 5.  Ocular metipranolol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in glaucoma and ocular hypertension.

Authors:  P E Battershill; E M Sorkin
Journal:  Drugs       Date:  1988-11       Impact factor: 9.546

Review 6.  Pharmacological therapy for glaucoma: a review.

Authors:  P F Hoyng; L M van Beek
Journal:  Drugs       Date:  2000-03       Impact factor: 9.546

7.  Topical timolol with and without benzalkonium chloride: epithelial permeability and autofluorescence of the cornea in glaucoma.

Authors:  C de Jong; T Stolwijk; E Kuppens; R de Keizer; J van Best
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1994-04       Impact factor: 3.117

Review 8.  Ocular beta-blockers in glaucoma management. Clinical pharmacological aspects.

Authors:  A M Brooks; W E Gillies
Journal:  Drugs Aging       Date:  1992 May-Jun       Impact factor: 3.923

9.  Long-term effect of latanoprost/timolol fixed combination in patients with glaucoma or ocular hypertension: a prospective, observational, noninterventional study.

Authors:  Oliver Schwenn; Barbara Heckmann; Claudia Guzy; Paul J Miller
Journal:  BMC Ophthalmol       Date:  2010-09-08       Impact factor: 2.209

10.  Recent advances in pharmacotherapy of glaucoma.

Authors:  S K Gupta; Galpalli Niranjan D; S S Agrawal; Sushma Srivastava; Rohit Saxena
Journal:  Indian J Pharmacol       Date:  2008-10       Impact factor: 1.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.